Collplant Biotechnologies Ltd (CLGN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $14.27M
Last updated: Nov 13, 2026 at 4:00 PM ET
Collplant Biotechnologies Ltd (CLGN) Stock Forecast
Analysts expect Collplant Biotechnologies (CLGN) to earn -$0.59 per share in the fiscal year ending Dec 31, 2026, on revenue of $6.11M. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$0.18.
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 24.9%.
- Fiscal year ending Dec 31, 2026
- -$0.59
- EPS consensus, revenue $6.11M
- Fiscal year ending Dec 31, 2027
- -$0.18
- EPS consensus, revenue $7.63M
- Fiscal year ending Dec 31, 2028
- -$0.17
- EPS consensus, revenue $3.00M
- Next report
- Nov 24, 2026
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.59 | -$0.59 to -$0.59 | 1 | $6.11M | $6.11M to $6.11M | 1 |
| Dec 31, 2027 | -$0.18 | -$0.18 to -$0.18 | 1 | $7.63M | $7.63M to $7.63M | 1 |
| Dec 31, 2028 | -$0.17 | -$0.17 to -$0.17 | 1 | $3.00M | $2.99M to $3.01M | 1 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 1 upward and 2 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 1 |
| Fiscal year ending Dec 31, 2027 | 1 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.05.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.59 | -$0.59 | -$0.42 | -$0.42 | -$0.05 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.18 | -$0.01 | -$0.03 | -$0.03 | -$0.02 | N/A |
Frequently Asked Questions About CLGN
What is the CLGN stock forecast?
Consensus analyst estimates put Collplant Biotechnologies's EPS at -$0.59 for the fiscal year ending Dec 31, 2026, on revenue of $6.11M.
What EPS do analysts expect from CLGN next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.59, with estimates from -$0.59 to -$0.59 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.18, with estimates from -$0.18 to -$0.18 from 1 analyst.
What revenue do analysts expect from Collplant Biotechnologies next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $6.11M, with estimates from $6.11M to $6.11M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $7.63M, with estimates from $7.63M to $7.63M.
How many analysts cover CLGN?
1 analyst estimates EPS for Collplant Biotechnologies for the fiscal year ending Dec 31, 2026.
CLGN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors